Asset Details
Do you wish to reserve the book?
Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours
Do you wish to request the book?
Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours
2020
Overview
Background
BAL101553 (lisavanbulin), the lysine prodrug of BAL27862 (avanbulin), exhibits broad anti-proliferative activity in human cancer models refractory to clinically relevant microtubule-targeting agents.
Methods
This two-part, open-label, phase 1/2a study aimed to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of 2-h infusion of BAL101553 in adults with advanced or recurrent solid tumours. The MTD was determined using a modified accelerated titration design in phase I. Patients received BAL101553 at the MTD and at lower doses in the phase 2a expansion to characterise safety and efficacy and to determine the recommended phase 2 dose (RP2D).
Results
Seventy-three patients received BAL101553 at doses of 15–80 mg/m
2
(phase 1,
n
= 24; phase 2a,
n
= 49). The MTD was 60 mg/m
2
; DLTs observed at doses ≥60 mg/m
2
were reversible Grade 2–3 gait disturbance with Grade 2 peripheral sensory neuropathy. In phase 2a, asymptomatic myocardial injury was observed at doses ≥45 mg/m
2
. The RP2D for 2-h intravenous infusion was 30 mg/m
2
. The overall disease control rate was 26.3% in the efficacy population.
Conclusions
The RP2D for 2-h infusion of BAL101553 was well tolerated. Dose-limiting neurological and myocardial side effects were consistent with the agent’s vascular-disrupting properties.
Clinical trial registration
EudraCT: 2010-024237-23.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ Adult
/ Aged
/ Benzimidazoles - administration & dosage
/ Benzimidazoles - adverse effects
/ Benzimidazoles - pharmacokinetics
/ Biomedical and Life Sciences
/ Female
/ Gait
/ Humans
/ Lysine
/ M Phase Cell Cycle Checkpoints - drug effects
/ Male
/ Oncology
/ Oxadiazoles - administration & dosage
/ Oxadiazoles - adverse effects
/ Oxadiazoles - pharmacokinetics
/ Prodrugs - administration & dosage
/ Spindle Apparatus - drug effects
/ Tumors
